Treatment of HER-2 Positive Breast Cancer is fastest growing segment fueling the growth of HER-2 Negative Breast Cancer Market

 The global HER-2 Negative Breast Cancer Market is estimated to be valued at US$ 13,873.7 Mn in 2023 and is expected to exhibit a CAGR of 10.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

HER-2 negative breast cancer lacks expression and/or amplification of human epidermal growth factor receptor 2 (HER2). Treatment for HER-2 negative breast cancer includes chemotherapy, hormonal therapy, radiation therapy, targeted therapy and surgery. The need for improved and targeted treatment drives the growth of this market.

Market key trends:
One of the key trends in the HER-2 Negative Breast Cancer Market is the development and approval of novel targeted therapies. Companies are focusing on development of targeted monoclonal antibodies and tyrosine kinase inhibitors (TKIs) to address unmet needs. For example, tucatinib, a tyrosine kinase inhibitor developed by Seattle Genetics, was approved by the US FDA in 2021 for treatment of advanced HER2-positive breast cancer in combination with trastuzumab and capecitabine. It acts as an oral, small molecule inhibitor of HER2. Similarly, trastuzumab deruxtecan, an antibody-drug conjugate, developed by Daiichi Sankyo was approved in 2019 for the treatment of patients with HER2-positive breast cancer. It selectively delivers chemotherapy inside HER2-positive cancer cells.

Segment Analysis
The global HER-2 negative breast cancer market is segmented based on treatment type and end-user. Based on treatment type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, surgery and radiation therapy, hormonal therapy, and others. Among these, the chemotherapy segment dominated the market in 2022 due to the frequent usage of chemotherapy drugs such as taxanes, anthracyclines and combinations for HER-2 negative breast cancer treatment.

Key Takeaways
The Global Her-2 Negative Breast Cancer Market Size is expected to witness high growth at a CAGR of 10.1% over the forecast period, due to increasing prevalence of breast cancer worldwide.

Regional analysis
North America dominated the global market in 2022 and is estimated to maintain its dominance over the forecast period. This is attributed to the increasing prevalence of breast cancer and developed healthcare infrastructure in the region. Asia Pacific is anticipated to exhibit fastest growth over the forecast period due to growing awareness about early detection of breast cancer and increasing healthcare expenditures.

Key players
Key players operating in the HER-2 negative breast cancer market are Pfizer Inc., Novartis AG, Merck & Co. Inc., GSK PLC, AstraZeneca, Eli Lilly and Company, and Bristol-Myers Squibb Company (Celgene Corporation), among others. Pfizer Inc. dominated the global market with its chemotherapy drugs such as docetaxel and paclitaxel indicated for breast cancer treatment.

Comments

Post a Comment

Popular posts from this blog

Vegan Yogurt Market is Poised for Growth Driven by Rising Health Consciousness

Image
Vegan yogurt is a dairy-free alternative to conventional yogurt made from plant-based milk such as soy, almond, oat, coconut or rice. It provides similar texture and taste to dairy yogurt but without any animal products.Vegan yogurt offers several health advantages over dairy yogurt as it is devoid of lactose, cholesterol and saturated fats. The growing number of people adopting vegan and flexitarian diets has driven the demand for plant-based dairy alternatives like vegan yogurt. The global vegan yogurt market is estimated to be valued at US$ 4.15 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024 to 2031. Key Takeaways Key players- Met Fods, Cocos Organic, Hain Celestial, EasiYo Product Limited, Danone, General Mills Inc., Stonyfield Far, Inc., Daiya Foods Inc.m Good Karma foods, Inc.m Hudson River Foodsm NANCY'S, Kite Hill, COYO Pty lTd., Nush Foods, Chobani, LLC, Barambah Oraganics Pty Ltd., Blue Diamond Growers, Dean Foodsm General Mills Inc...
Read more

Hypoglycemic Drugs Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Diabetes in the Geriatric Population

Image
Hypoglycemic drugs or anti-diabetic drugs are medications used to treat diabetes mellitus by lowering blood glucose levels. Some key hypoglycemic drugs include insulin, sulfonylureas, metformin, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists. These drugs help control blood sugar levels in diabetics and prevent or delay diabetes-related health complications. The global hypoglycemic drugs market is estimated to be valued at US$ 720.72 Mn in 2023 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Dynamics: The growth of the global hypoglycemic drugs market is majorly driven by the increasing prevalence of diabetes in the geriatric population globally. As per estimates, around 1 in every 11 people aged 65 years and above have diabetes. Further, the number of people with diabetes in this age group is anticipated to grow from 25.9 million in 2017 to...
Read more

Clinical Trials Rising with Digital Technologies Adoption

Image
 Clinical trials support services play a vital role in assisting sponsors and life science companies to conduct clinical trials in a precise and well-organized manner.These services assist pharmaceutical companies in patient recruitment, data management, site management, and overall clinical trial management. With rising complexities in clinical trials owing to integration of technologies like telehealth and remote patient monitoring, the demand for these support services is growing substantially. The global Clinical Trials Support Services Market is estimated to be valued at US$ 22.38 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: The growing adoption of digital technologies across clinical trials is a key trend accelerating the growth of the clinical trials support services market. Digital tools like electronic data capture, clinical trial manag...
Read more